Study drug for advanced solid tumors that stopped responding
Part of Cancer clinical trials.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor confirmed by a lab test (biopsy or cytology).
- Your usual standard treatments have failed, or you have no standard option, or you couldn’t tolerate standard treatment.
- Your daily function is good: you are fully active or limited only a little (ECOG performance status 0 or 1).
- You expect to live at least 3 months.
- You have at least one measurable tumor spot on scans that can be tracked over time; if a spot was previously treated with radiation, it must have grown again after radiation.
- A study doctor must agree you’re suitable to join (they can exclude you for safety or other concerns).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (ZG005) combined with another drug (gecacitinib) and chemotherapy to see if it can help people with advanced solid tumors, especially cancer of the stomach or esophagus. The goal is to find a new treatment option that might be more effective than current approaches.
This trial tests a new experimental medicine called SGT003 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the medicine is safe, how the body handles it, and whether it can shrink tumors or slow their growth.
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.